Nuclear Medicine/Radiopharmaceuticals Market

Cardinal Health (US) and Curium (France) are the Key Players in the Nuclear Medicine/Radiopharmaceuticals Market

The nuclear medicine market is expected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence & prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

The major players in the nuclear medicine market are Cardinal Health (US), GE Healthcare (US), Curium (France), and Bayer AG (German). An analysis of the market developments between 2017 and 2019 revealed that product launches, partnerships, and expansions, were adopted by market players to strengthen their product portfolios and maintain a competitive position in the contrast media industry.

Cardinal Health (US) is one of the major players in the nuclear medicine market. It is a healthcare services company providing pharmaceutical and medical products and services to healthcare providers. Cardinal Health operates in the US, Canada, the British Virgin Islands, Malaysia, Singapore, the UK, Luxembourg, Thailand, Switzerland, Ireland, and Belgium through its 150 subsidiaries. Its global presence enables the company to operate the world’s largest network of nuclear pharmacies and expand its PET agent manufacturing capabilities to support new drug development and the growth of personalized medicine. The company has expanded its production capabilities in the US by opening three new cyclotrons in Sacramento, Portland, and Chicago.

To know about the assumptions considered for the study download the pdf brochure

Curium (France) is another one of the major players in the nuclear medicine market. Curium started its operations in 2017 through the union of two major players—IBA Molecular (France) and Mallinckrodt Pharmaceuticals (Ireland)-in the nuclear medicine market. The company focuses on innovation and it invested ~USD 3 million to build a new R&D laboratory in 2017. The company is planning to introduce four new products, which are likely to lead to a multifold increase in its revenue. With a strong, experienced workforce that has an extensive background in nuclear medicine and a steady focus on innovation, the company is likely to dominate the global nuclear medicine market in the coming years.

GE Healthcare (US) has a huge network of radiopharmacies and a robust customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa. Some major subsidiaries of the company are GE Healthcare USA Holdings, GE Healthcare (Japan), GE Healthcare Biosciences AB (US), and GE Healthcare AS (Norway). The company’s robust portfolio for the nuclear medicine market, large number of subsidiaries, and focus on customer satisfaction has contributed to its large share in the nuclear medicine market.

Related Reports:

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
PH 3590
RI Published ON
1/27/2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine/Radiopharmaceuticals Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved